Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Pharmaceutical K.K.
Age
20–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of metastatic, hormone-naïve prostate cancer (mHNPC) after 1 May 2019
Should have at least 2 of the 3 following high-risk factors: a Gleason score of greater than or equal to (\>=) 8, at least 3-bone lesions, or the presence of visceral metastasis
Willing to receive androgen-deprivation therapy (ADT) containing regimens for high-risk metastatic, hormone-naïve prostate cancer (mHNPC) in the hospital which have the contract with sponsor for this study, or patient received a regimen containing ADT for high-risk mHNPC
Possess Japanese nationality
Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and procedures required for the study and is willing to participate in the study. For dead cases, the ICF can be waived after approved by Independent Ethics Committee/Institutional Review Board (IEC/IRB)
